Initiate a confirmatory trial of bitopertin in EPP

Delivered by the deadline

AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.

Announced: 8 Nov 2024
Due: 30 Jun 2025
Delivered: May 2025

Deadline
Met
Late
Not met
Today

What the company said

“potential initiation of a confirmatory trial of bitopertin in EPP by mid-2025”

SourceDisc Medicine, Inc. Form 8-K press release, 2024-11-08
FilingSEC filing index
Deadline as statedby mid-2025
Deadline used30 Jun 2025, the last day of the stated period
TypeProject
Permanent referenceKI-C-2024-IRON-002177
Cite as https://keptindex.org/c/KI-C-2024-IRON-002177/ — this address never changes.

What we found

Evidence strength A What the grades mean

The company initiated the APOLLO clinical trial, which serves as the confirmatory trial for bitopertin in EPP, in May 2025, meeting the mid-2025 deadline.

A
Disc Medicine, Inc. 10-Q filed 2025-08-07 Regulatory filing · published 7 Aug 2025 · retrieved 1 Oct 2026 · kept permanently by the SEC · fingerprint 53d7fac14eed
“We initiated the APOLLO trial in May 2025.” ✓ confirmed on the page

Market reaction: the shares moved -1.2% against the S&P 500 over the three sessions around the disclosure (6 Aug 2025 to 11 Aug 2025). What this measures

Checked 1 Oct 2026.

Commitment lineage

Every time the company restated this commitment. The original is never changed, and the outcome is always measured against version 1.

2 versions

Version 1 · original · stated 8 Nov 2024

Deadline 30 Jun 2025 (“by mid-2025”)
Version 2 · stated 12 Nov 2024

Deadline 30 Jun 2025 (“by mid-2025”) · wording expected

“plans to initiate this trial by mid-2025.”
Source for this version

Commitment DNA

The structured record of this commitment. Fields the company did not state are left blank rather than guessed.

Event type: Clinical milestone
Indicative materiality: Medium rules
Action: Initiate
Deliverable: confirmatory trial of bitopertin in EPP
In the company’s control: High
Specificity: High

How this entry was checked

Commitment recordedThe company's words were matched word for word against the filing.
First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
Second check: disagreesClaude (Anthropic) re-read the evidence blind and read it as “Late”.
Tie-breakA stronger model read the evidence and both earlier answers, without knowing which was recorded, and agrees with the recorded outcome.

Confirmed. This outcome counts towards the company's Kept Score. How verification works

Are you Disc Medicine, Inc.? You can publish an official statement next to this entry, free. Add a statement.

Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.

Report an error in this entry Reference: KI-C-2024-IRON-002177 · Corrections policy